Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 2/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130905 | 0.86 | AXL (0.37) | AXLNUDT1BRD4CDK8APP | |
| SCHEMBL11886176 | 0.76 | AXL (0.35) | AXLNUDT1BRD4APP | |
| SCHEMBL4167148 | 0.76 | AXL (0.41) | AXLNUDT1BRD4CDK8FGFR1 | |
| SCHEMBL11888031 | 0.73 | AXL (0.38) | AXLNUDT1BRD4FGFR1KDR | |
| SCHEMBL28057850 | 0.72 | LTB4R (0.35) | AXLNUDT1BRD4 | |
| SCHEMBL6929283 | 0.72 | CCR1 (0.50) | AXLNUDT1BRD4CDK8APP | |
| SCHEMBL6928507 | 0.72 | CCR1 (0.50) | AXLNUDT1BRD4CDK8APP | |
| SCHEMBL31283256 | 0.72 | AXL (0.41) | AXLNUDT1BRD4CDK8APP | |
| SCHEMBL5925823 | 0.71 | AXL (0.37) | AXLNUDT1BRD4APP | |
| SCHEMBL18430380 | 0.71 | AXL (0.37) | AXLNUDT1BRD4APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210179599-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | NR1H2, NR1H4, NR1H3 | AXL 1076/4885NUDT1 2584/4885BRD4 3252/4885 |
| US-20210179599-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H2, NR1H4, NR1H3 | AXL 1076/4885NUDT1 2584/4885BRD4 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.